Approaches to antiviral drug development.
At present, only a few drugs have been approved by the FDA for therapy of viral infections in humans. There is a great need for antiviral drugs with increased potency and decreased toxicity, as well as drugs to treat viral diseases for which no drug or vaccine is currently available. Two approaches for development of antiviral drugs are described--an empirical strategy and a rational strategy--with several examples of each. Although many compounds have potent antiviral activity in cell culture, only a small fraction of these will go on to become antiviral drugs for use in humans. At this time, only seven synthetic compounds and alpha interferon have been approved by the FDA for therapy of viral infections in humans. None of these approved drugs are without toxicities, however, and hence there is a great need for antiviral drugs with increased potency and decreased toxicity, as well as for drugs to treat viral diseases for which no drug or vaccine is currently available. Two approaches for the development of antiviral drugs--the empirical and the rational strategies--and their applications and future directions are discussed.
Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510.
W H
WH
Prusoff
T S
TS
Lin
E M
EM
August
T G
TG
Wood
M E
ME
Marongiu
D000998:Antiviral Agents / Q000494:pharmacology; D001665:Binding Sites; D015195:Drug Design; D005814:Genes, Viral; D013329:Structure-Activity Relationship; D013937:Thymidine Kinase / Q000037:antagonists & inhibitors; D014481:United States; D014486:United States Food and Drug Administration; D014777:Virus Diseases / Q000628:therapy*; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D013937:Thymidine Kinase